Capital to be invested in company’s AI platform and discovery pipeline.
Genesis Therapeutics, an artificial intelligence (AI) technology company, has officially closed series B funding with an oversubscribed total of $200 million. Reportedly, the newly acquired funds will be used to advance its pipeline of AI-enabled programs into clinical development. Genesis also intends on initiating new programs for underserved patient populations and leveraging the Genesis Exploration of Molecular Space (GEMS) platform to make progress against challenging and previously undruggable targets.
“AI presents a potent opportunity to revolutionize the drug discovery process, which frequently struggles to produce viable drug candidates against targets that are biologically well-validated but considered undruggable due to highly challenging chemistry,” said Evan Feinberg, PhD, CEO, Genesis Therapeutics, in a company press release. “This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic. The addition of our new lead investor, and other meaningful additions to our biotech and AI-oriented syndicate, will support Genesis in developing breakthrough therapies for patients with severe unmet medical needs, and their families, capitalizing on the broad applicability and potential of the GEMS AI platform.”
Reference: Genesis Therapeutics Closes Oversubscribed $200 Million Series B. BusinessWire. August 21, 2023. Accessed August 22, 2023. https://www.businesswire.com/news/home/20230821419353/en/Genesis-Therapeutics-Closes-Oversubscribed-200-Million-Series-B
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.